Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A

NCT03528551 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03528551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2018
Completion date
December 3, 2020
Enrollment
160 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a